Nuclear transfer and iPS may work best together.
A short meeting, held as an Arthur Sackler Colloquium of the United States National Academy of Sciences, was organized by Douglas Wallace, Susan Bryant, and Peter Donovan under the heading "Therapeutic Cloning: Where Do We Go from Here?" on October 8 and 9, 2007. The individual components required for therapeutic cloning now exist. The question, therefore, is what constraints presently limit or prevent its application to human therapy.
Gurdon
John
J
Wellcome Trust/Cancer Research UK Gurdon Institute, The Henry Wellcome Building of Cancer and Developmental Biology, Tennis Court Road, Cambridge CB2 1QN, UK. j.gurdon@gurdon.cam.ac.uk
Murdoch
Alison
A
D053687:Adult Stem Cells / Q000166:cytology; D000818:Animals; D002460:Cell Line; D065150:Cellular Reprogramming; D002999:Clone Cells / Q000166:cytology; D004989:Ethics; D005347:Fibroblasts / Q000166:cytology; D006801:Humans; D051379:Mice; D053652:Nuclear Transfer Techniques; D010063:Ovum / Q000166:cytology*; D039904:Pluripotent Stem Cells / Q000166:cytology*; D011817:Rabbits; D012867:Skin / Q000166:cytology*; D014981:Xenopus